Hemispheric.ai
Foundational AI for Non-invasive Brain Decoding
Company Overview
Snapshot
Founded in September 2019 by Hagai Lalazar and Gidi Littwin, Hemispheric.ai operates with 51–200 employees. The company has raised $52 million across two funding rounds from 8 investors. In July 2026, Hemispheric.ai secured a significant funding round, emerging from stealth mode.
Business overview
Hemispheric.ai is developing a foundational AI platform designed for decoding non-invasive brain signals. Its core technology, a Large Brain Model, utilizes deep learning to analyze neural-signal data. This platform supports various brain-computer interface applications across critical sectors including healthcare, consumer products, and defense. The company operates within the Health Tech & Life Sciences sector, focusing on digital healthcare and medical technologies.
Strategic signal
In July 2026, Hemispheric.ai emerged from stealth mode, announcing a $52 million funding round. This public debut and substantial capital infusion signal strong investor confidence in the company's foundational AI platform for non-invasive brain decoding, positioning it as a significant player in the rapidly evolving neuro-AI and brain-computer interface markets.
Log in to access full profile ›Company Intelligence Q&A
- What is Hemispheric.ai's primary focus?
- Hemispheric.ai focuses on developing a foundational AI platform for decoding non-invasive brain signals, utilizing a Large Brain Model that applies deep learning to neural-signal data.
- When was Hemispheric.ai founded?
- Hemispheric.ai was founded in September 2019.
- Who are the founders of Hemispheric.ai?
- Hemispheric.ai was co-founded by Hagai Lalazar and Gidi Littwin.
- What was a significant recent development for Hemispheric.ai?
- In July 2026, Hemispheric.ai emerged from stealth mode, announcing a $52 million funding round.
- Which investors participated in Hemispheric.ai's July 2026 funding round?
- The July 2026 funding round for Hemispheric.ai included participation from Protocol Labs and Artofin.